KNSA vs BIIB: Which Stock is Better?

Side-by-side comparison of Kiniksa Pharmaceuticals International Plc and Biogen Inc in 2026

Comparison Updated:

KNSA

Kiniksa Pharmaceuticals International Plc

$47.30

BIIB

Biogen Inc

$176.37

Key Metrics Comparison

MetricKNSABIIBWinner
Market Cap$3.60B$25.38BBIIB
P/E Ratio62.7719.68BIIB
EPS (TTM)$0.75$8.79BIIB
Revenue Growth0.7%-0.1%KNSA
Gross Margin54.7%78.9%BIIB

Analyze KNSA

Full quant analysis

Analyze BIIB

Full quant analysis

Analyze Each Stock

Frequently Asked Questions

Is KNSA or BIIB a better investment?

Comparing KNSA and BIIB: Kiniksa Pharmaceuticals International Plc has a market cap of $3.60B while Biogen Inc has $25.38B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.

What is the difference between KNSA and BIIB?

KNSA (Kiniksa Pharmaceuticals International Plc) and BIIB (Biogen Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.

Which stock has better value: KNSA or BIIB?

Based on P/E ratios, BIIB trades at a lower multiple (19.7x vs 62.8x).

Which is growing faster: KNSA or BIIB?

KNSA has higher revenue growth at 0.7% vs -0.1% for BIIB.

Which company is more profitable: KNSA or BIIB?

Biogen Inc (BIIB) has higher gross margins at 78.9% compared to 54.7% for KNSA.

Which is the larger company: KNSA or BIIB?

Biogen Inc (BIIB) is larger with a market cap of $25.38B compared to $3.60B for KNSA.

Should I buy KNSA or BIIB in 2026?

Both KNSA and BIIB have investment merit. KNSA trades at $47.30 while BIIB trades at $176.37. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.

What are the key differences between KNSA and BIIB stock?

Key differences: Market Cap ($3.60B vs $25.38B), P/E Ratio (62.8x vs 19.7x), Revenue Growth (0.7% vs -0.1%), Gross Margin (54.7% vs 78.9%).

Popular Stock Comparisons